. 2021 Jul 5;36(11):3050–3055. doi: 10.1111/jgh.15591

Table 1.

Demographic characteristics, clinical data, and outcome of IBD patients who developed COVID‐19 on biologic therapy

Patient	IBD type	IBD duration (years)	Therapy	Comorbidities	Diagnosis	Symptoms	Hospitalization	Clinical course	Outcome
#1	CD	12	Vedolizumab	COPD, AF, arterial hypertension, obesity	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia	Dead
78, F	CD	12	Vedolizumab	COPD, AF, arterial hypertension, obesity	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia	Dead
#2	CD	11	Adalimumab	None	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia, acute kidney injury	Recovered
26, M	CD	11	Adalimumab	None	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia, acute kidney injury	Recovered
#3	UC	1	Vedolizumab, 5‐ASA, steroids	None	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia, NIV therapy	Recovered
65, F	UC	1	Vedolizumab, 5‐ASA, steroids	None	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia, NIV therapy	Recovered
#4	UC	15	Vedolizumab	None	Serology	Mild respiratory symptoms	No	—	Recovered
68, F	UC	15	Vedolizumab	None	Serology	Mild respiratory symptoms	No	—	Recovered
#5	UC	14	Vedolizumab	None	Swab	Fever, respiratory symptoms	No	—	Recovered
39, M	UC	14	Vedolizumab	None	Swab	Fever, respiratory symptoms	No	—	Recovered
#6	UC	26	Vedolizumab	None	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia, ICU admission, tracheal intubation	Dead
56, M	UC	26	Vedolizumab	None	Swab	Fever, respiratory symptoms	Yes	Interstitial pneumonia, ICU admission, tracheal intubation	Dead
#7	CD	6	Ustekinumab	Arterial hypertension	Serology	Mild respiratory symptoms	No	—	Recovered
47, F	CD	6	Ustekinumab	Arterial hypertension	Serology	Mild respiratory symptoms	No	—	Recovered

5‐ASA, 5‐aminosalicylic acid; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; CD, Crohn's disease; F, female; IBD, inflammatory bowel disease; M, male; UC, ulcerative colitis.